Valion Bio, Inc.

NasdaqCM:VBIO Stock Report

Market Cap: US$2.1m

Valion Bio Management

Management criteria checks 2/4

Valion Bio's CEO is Mike Handley, appointed in Mar 2026, has a tenure of less than a year. total yearly compensation is $735.03K, comprised of 35.5% salary and 64.5% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $7.24K. The average tenure of the management team and the board of directors is 0.3 years and 4.4 years respectively.

Key information

Mike Handley

Chief executive officer

US$735.0k

Total compensation

CEO salary percentage35.54%
CEO tenureless than a year
CEO ownership0.4%
Management average tenureless than a year
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 17

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Health technology company Tivic Health Systems (NASDAQ:TIVC) will acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies. The total consideration is of up to $33.5M, of which up to $1.5M can be paid in restricted common stock. TIVC will also acquire Reliefband's Reletex-branded prescription nausea treatments. Reliefband Technologies' patented products are backed by 40 peer-reviewed clinical studies. The transaction is expected to be consummated in Q4 or Q1 2023. The nausea treatment is a $2.4B market in the U.S. and $5.5B globally, according to QY Research. The market is said to be growing at 6.5% CAGR. TIVC shares were trading +14.57% pre-market. Source: Press Release
Analysis Article • Jul 15

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Mike Handley's remuneration changed compared to Valion Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$13m

Dec 31 2025US$735kUS$261k

-US$8m

Compensation vs Market: Mike's total compensation ($USD735.03K) is about average for companies of similar size in the US market ($USD631.70K).

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.

CEO

Mike Handley (54 yo)

less than a year
Tenure
US$735,027
Compensation

Mr. Michael Kevin Handley, also known as Mike, is Independent Director of Statera Biopharma, Inc. Mr. Handley served as President of Tivic Biopharma at Valion Bio, Inc. (formerly known as Tivic Health Syst...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Handley
CEO & Directorless than a yearUS$735.03k0.35%
$ 7.2k
Lisa Wolf
CFO and Principal Financial & Principal Accounting Officer1.7yrsUS$574.78k0.017%
$ 345.5
Melinda Lackey
General Counsel & Senior Vice President of Legal Affairsless than a yearno datano data
0.3yrs
Average Tenure
54yo
Average Age

Experienced Management: VBIO's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Michael Handley
CEO & Directorless than a yearUS$735.03k0.35%
$ 7.2k
Sheryle Bolton
Independent Chair of the Board6.9yrsUS$117.00k0.32%
$ 6.6k
Christina Valauri
Independent Director1.9yrsUS$66.60k0.61%
$ 12.5k
J. Zikria
Independent Director6.9yrsUS$59.10k0%
$ 0
4.4yrs
Average Tenure
57yo
Average Age

Experienced Board: VBIO's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 06:15
End of Day Share Price 2026/06/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Valion Bio, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hunter DiamondDiamond Equity Research LLC